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rEpidemiology
Behavioral factors, health parameters, and outcomes in
the United States. Ideal cardiovascular health was defined
as the combination of 7 behavioral factors and health
parameters (Table 1) (1). Unfortunately, a recent U.S.
survey indicated that only 37% of persons could correctly
identify these ideal health components (2). Among middle-
aged Americans, mostly free from cardiovascular disease
(CVD), the prevalence of ideal health is 0.1%, 80% of
people display poor health in at least 1 category, and the
number of health factors relates to outcomes (Fig. 1) (3,4).
Cardiovascular risk trends and costs. The Global Burden
of Metabolic Risk Factors of Chronic Diseases Collaborat-
ing Group published a number of reports reviewing trends
in cardiovascular risk control worldwide since 1980. Men
and women experienced mean increases in fasting glucose of
1.3 mg/dl and 1.6 mg/dl, respectively, as well as increments
in body mass index of 0.4 kg/m2 and 0.5 kg/m2, respec-
ively, per decade. The prevalence of obesity and diabetes
ellitus approximately doubled (5,6). Some risk factors
howed slight improvements (systolic blood pressure de-
reased 0.8 to 1.0 mm Hg, and total cholesterol levels by up
o 1.8 mg/dl), although less pronounced in low- and
iddle-income countries (7,8). In the United States, CVD
revalence was projected to increase by 10%, indirect costs by
1%, and direct costs by 200% in the next 2 decades (Fig. 2) (9).
lthough the incidence of ST-segment elevation myocar-
ial infarction has decreased in developed countries, most
rst fatal events due to coronary heart disease (CHD) still
ccur outside of the hospital without the chance of bene-
ting from therapeutic interventions (10), thus reemphasiz-
ng the importance of prevention. Moreover, a study re-
orted that nearly one-half (43%) of major CHD events
ccurred in the minority of patients (6%) with prior mani-
est disease (11).
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icroribonucleic acid and monocytes in atherosclerosis.
onocytes recruited into the vessel wall carry their microri-
onucleic acid (microRNA), allowing for characterization of
lassical and nonclassical activated monocytes in atheroscle-
osis (12). A high increase of microRNAs from classically
ctivated monocytes was documented in human carotid
laques. Many of the microRNAs detected in blood and
laque tissue were consistent with previously documented
oles in development of myeloid cells, cytokine production,
rotection from apoptosis, and differentiation into dendritic
ells (13).
eoatherosclerosis. The presence of new atheroma within
tents was documented by several groups. In the largest
athology study evaluating 400 stents, the incidence of
eoatherosclerosis was significantly higher for drug-eluting
tents than bare-metal stents (31% vs. 16%; p 0.001), and
hin-cap fibroatheroma or plaque rupture was present in 4%
f bare-metal stents and 1% of drug-eluting stents, although
nterval since implantation was shorter for drug-eluting
tents (1.5 vs. 6.1 years) (14). In a study using optical
oherence tomography, neoatherosclerosis was noted in
2% of drug-eluting stents after 32 months of deployment,
nd patients with unstable angina had increased incidence of
hin-cap fibroatheroma and plaque rupture (15). Finally, in
spiration thrombectomy samples of patients with bare-
etal stent thrombosis, patients presenting 3 years after
eployment exhibited the highest incidence of foamy mac-
ophages, cholesterol crystals, and thin fibrous cap frag-
ents, suggesting neoatheroma rupture as a pivotal mech-
nism for very late stent thrombosis (16).
laque angiogenesis. Adventitial neovascularization in
polipoprotein E-deficient (apoE/) mice was associated
ith increased plaque size (17), and new evidence emerged
orrelating neovascularization with inflammation, intra-
laque hemorrhage and reparative type III collagen in
uman atheroma from diabetic patients (18). Both
ngiotensin-receptor blockers and statins led to reduced
eovessel content in apoE/ mice when compared to
lacebo (19,20). However, direct antiangiogenic therapy
sing vascular endothelial growth factor inhibitors was
ssociated with thromboembolism in patients with age-
elated macular degeneration (21). The mechanisms in-
olved may include systemic hypertension, impaired endo-
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later form of reverse angiogenesis may be responsible for the
microvascular deterioration linking atherosclerosis with dif-
ferent forms of dementia (23).
Conventional cardiovascular risk factors, degenerative
brain disease, and Alzheimer’s disease. Links between
cardiovascular risk factors, vascular disease, and aging (24)
continued to be documented. In models adjusted for age,
ethnicity, marital status, and education, increments in the
Framingham risk score were associated with faster decline in
cognitive function in both middle-aged men and women
without apparent CVD (25). In addition, documented
peripheral vascular disease was highlighted as a marker for
cognitive impairment and progression to dementia (26).
Early Detection and Risk Stratification
Conventional risk factors. From the INTERHEART
study, scores with and without laboratory-based variables
Figure 1 Relation Between Components of Ideal Cardiovascula
Incident cardiovascular disease (CVD) adjusted for age, race, and sex in the ARIC
Reproduced with permission from Folsom et al. (4).
Components of Ideal Cardiovascular HealthTable 1 Components of Ideal Cardiovascular Health
Recommended physical activity pattern
Recommended dietary pattern
Absence of smoking
Body mass index 25 kg/m2
Untreated total cholesterol 200 mg/dl
Untreated blood pressure 120/80 mm Hg
Untreated fasting glucose 100 mg/dl
Adapted from Lloyd-Jones et al. (1).for the prediction of myocardial infarction were developed
and validated in a multiethnic and multigeographic popu-
lation (27). Both the Framingham and the Reynolds scores
were able to predict incidence and progression of coronary
artery calcification similarly (28).
Across the world, secondhand smoking directly caused
600,000 deaths, more than one-half related to CHD (29).
Moreover, parental smoking was linked to higher blood
pressure and lower high-density lipoprotein (HDL) choles-
terol in young children (30,31). For unclear reasons, the
relative risk of smoking-related CHD was 25% higher in
women after adjusting for other confounders (32). A higher
body mass index in adolescence (even within the range
considered normal) was independently associated with
CHD in adulthood (33). However, the risk profiles of adults
who were obese during childhood and then became nono-
bese were comparable to those of adults who were never
obese (34). Previous research identified obesity as an inde-
pendent risk factor for CVD, but prospective data from
220,000 apparently healthy persons demonstrated no
incremental ability of either the body mass index, waist
circumference, or waist-to-hip ratio over conventional risk
factors to predict incident CVD (35). Conversely, parental
history of myocardial infarction (36) or cardiorespiratory
fitness (37) may provide additive prognostic value over
standard risk factors. Regarding blood lipids, a meta-
analysis of 12 studies including nearly 23,000 events indi-
cated better predictive ability of apolipoprotein B than
either low-density lipoprotein (LDL) or non-HDL choles-
lth and Outcome
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prevented by targeting this lipid fraction (38).
Serum and genetic biomarkers. Despite the failure of
prior trials using homocysteine-lowering therapies to reduce
events, a potential role for homocysteinemia in risk strati-
fication in asymptomatic persons was supported by com-
bined data from 2 large cohorts (39). Both positive and
negative findings were reported regarding the ability of
C-reactive protein (CRP) to independently predict cardio-
vascular outcomes in asymptomatic subjects (40,41). Simi-
larly, prior studies have not shown clear relationships
between CRP and atherosclerosis burden; an investigation
using computed tomography (CT) coronary angiography in
asymptomatic subjects reported independent associations of
elevated CRP with mixed coronary plaques, but not other
subtypes (42). In a 9-year prospective study of 3,649 men
aged 60 to 79 years, N-terminal pro-brain natriuretic
peptide but not CRP demonstrated incremental value over
traditional risk factors for the prediction of major CVD
events in the settings of both primary and secondary
prevention (43). Finally, quantification of troponin T
plasma levels with high-sensitivity assays was confirmed to
independently predict cardiovascular events in apparently
healthy persons (44).
A study involving 80,000 adoptees suggested that
ransmission of CHD from parents to offspring is more
trongly related to genetic than to familial environmental
actors (45). Meta-analyses of genome-wide association
tudies identified novel loci linked to subclinical athero-
hrombosis and clinical CHD (46–48). Importantly, only
few of these newly recognized variants relate to known risk
factors, indicating potentially unidentified pathways in the
pathogenesis of atherothrombosis. Another genome-wide
association study including 15 population-based cohorts
identified multiple genetic variants (mostly related to im-
mune and metabolic regulatory pathways) associated with
increased CRP levels but not to higher CHD risk (49).
Invasive imaging. In nearly 3,500 patients enrolled in 7
serial intravascular ultrasound (IVUS) trials, concomitant
peripheral artery disease was correlated with increased
Figure 2 Projected Increases in CVD Prevalence and Related C
(A) Crude prevalence and (B) costs related to cardiovascular disease (CVD) are expecburden of coronary atherosclerosis, concentric remodeling, cand atheroma progression (50). IVUS plaque features were
related to outcomes in the PROSPECT (Providing Re-
gional Observations to Study Predictors of Events in the
Coronary Tree) study (51). Nearly 700 patients with an
acute coronary syndrome underwent triple-vessel IVUS and
were followed up for a median of 3.4 years. Recurrent events
(mostly readmissions) occurred in approximately 20% of the
patients, and approximately 50% of these were related to
nonculprit lesions. Large plaque burden, small luminal area,
and presence of a thin-cap fibroatheroma on virtual histol-
ogy were IVUS-based variables predictive of events from
nonculprit lesions (Fig. 3). Using optical coherence tomog-
raphy, the median minimal cap thickness measured in vivo
in ruptured plaques was 54 m in comparison with 80 m
for nonruptured lesions. A value of 67 m was identified
s the optimal cutoff to predict rupture, which is in close
greement with the value of 65 m derived from histo-
athology studies (52).
oninvasive imaging. Data from the Framingham Off-
pring study revisited the potential of quantification of
arotid intima-media thickness (CIMT) for risk stratifica-
ion in primary prevention. The CIMT provided very
odest additive information to the Framingham risk score,
lightly improved by inclusion of plaque presence (53). The
IMT, however, and as opposed to coronary calcification
etected with CT, was not useful for further risk stratifica-
ion in participants of the MESA (Multi-Ethnic Study of
therosclerosis) trial who had low LDL cholesterol levels
130 mg/dl) (54). Selecting MESA participants with low
DL cholesterol and high CRP levels, such as those in the
UPITER (Justification for the Use of Statins in Primary
revention: an Intervention Trial Evaluating Rosuvastatin)
tudy, 74% of all CHD events occurred in the 25% of
ubjects with a calcium score 100, with an excellent
utcome for the nearly 50% of participants with a score of
ero (40). Nonetheless, in this and another large prospective
tudy, coronary calcification was a substantially stronger
redictor of outcomes than CRP in primary prevention, and
RP added no or marginal additional information to the
alcium score (40,41). Regarding the prognostic value of
in the United States
increase markedly during the next 2 decades. Data from Heidenreich et al. (9).osts
ted tooronary CT angiography, a meta-analysis of 18 studies and
935JACC Vol. 60, No. 10, 2012 Sanz et al.
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annual rate of myocardial infarction or death in the presence
of obstructive disease versus 0.15% (p  0.05) for a normal
study (55). Importantly, nonobstructive atherosclerosis on
CT angiography also had a negative impact on mortality
after accounting for conventional risk factors (56).
Magnetic resonance imaging (MRI) can depict intra-
plaque hemorrhage as areas of high signal intensity. A
pathogenic role of this finding in cerebrovascular events was
reinforced by an investigation demonstrating increased ip-
silateral brain ischemia and microembolic activity in the
presence of intraplaque bleeding (57). Moreover, high signal
intensity noted in carotid plaques (Fig. 4) was the strongest
independent predictor of coronary events (hazard ratio
[HR]: 3.2, 95% confidence interval [CI]: 1.9 to 5.6; p 
0.0001) in 217 patients with stable CHD followed up for
mean of 38 months (58). The feasibility of visualizing
intracoronary thrombus in acute coronary syndromes with
MRI was also reported (59).
Molecular and experimental imaging. Serial ultrasonog-
raphy using microbubbles was employed to successfully
track changes in plaque neovascularization in experimental
atherosclerosis (60). Investigations using positron emission
tomography demonstrated anti-inflammatory effects of pi-
oglitazone on atherosclerotic plaques both in animal models
(61) and in humans (62). Another interesting ex vivo study
indicated that tracer activity on positron emission tomog-
raphy may reflect not only inflammatory burden but also
hypoxia (63). A pilot human study suggested that increased
inflammation as determined by enhanced uptake of iron
oxide ultrasmall superparamagnetic particles on MRI pre-
dicts rapid growth of abdominal aortic aneurysms (64). In
addition, iron oxide particles targeted with oxidation-
specific antibodies could be detected within atherosclerotic
Figure 3 Event Rates in the PROSPECT Study According to IVU
Graphs compare event rates in the PROSPECT (Providing Regional Observations to
(TCFA [example shown in box]) (red bars), n  595, versus non-TCFA lesions (blu
den (PB). CI  confidence interval; IVUS  intravascular ultrasonography. Reprodulesions in mice (65). Other MRI contrast agents with highaffinity for matrix metalloproteinases or elastin were used to
track changes in arterial remodeling in experimental models
(66,67). Finally, a novel intravascular catheter was devel-
oped and validated for 2-dimensional in vivo near-infrared
fluorescence imaging of increased protease activity in ath-
erosclerotic plaques (68).
Prevention and Treatment
Adequacy of risk factor control. A study from Europe
involving7,500 patients without known CVD and at least
1 risk factor indicated that adequate risk factor control is
achieved in 40% of persons (69). Similarly, the multina-
tional REACH (Reduction of Atherothrombosis for Con-
tinued Health Registry) study indicated that 60% of
patients at high risk for or with established atherothrom-
bosis reached3 guideline-recommended risk factor targets
(70). In the United States, in patients with stable CHD
undergoing percutaneous intervention, optimal medical
therapy remains largely under-utilized (71). Insufficient use
of secondary prevention drugs could be particularly harmful
for patients with peripheral arterial disease, who may go
unrecognized (72). Furthermore, secondary prevention is
remarkably low across the world according to the multina-
tional PURE (Prospective Urban Rural Epidemiological)
study (73). That is especially troublesome in middle- and
low-income countries, which carry a large burden of CVD
but where as many as 80% of patients may receive no
preventive drugs at all (Fig. 5). The Institute of Medicine’s
recommendations for promoting global cardiovascular
health, with a particular emphasis on lower income coun-
tries, were summarized elsewhere (74).
Drug affordability and adherence. Improving drug avail-
sed Plaque Features
Predictors of Events in the Coronary Tree) study of thin-cap fibroatheromas
), n  2,114, and also according to minimal luminal area (MLA) and plaque bur-
ith permission from Stone et al. (51).S-Ba
Study
e bars
ced wability and affordability is crucial for CVD control in
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economies. A study from the United States randomized
nearly 6,000 post–myocardial infarction patients to a stan-
dard prescription plan with associated out-of-pocket costs
or to full coverage. Medication adherence was 4% to 6%
higher, and patient spending was 26% lower (p  0.001)
in the group receiving complete coverage, without an
increase in overall healthcare costs. This was associated
with significant reductions in events in the full-coverage
group (21.5% vs. 23.3%, HR: 0.89; p  0.03) (76). It was
estimated that a polypill (another potential approach to
improve therapy affordability and adherence) containing
aspirin, statin, angiotensin-converting enzyme inhibitor,
and beta-blocker could reduce the 10-year incidence of
CHD and stroke by 32% and 30%, respectively, in U.S.
patients with prior CVD. A similar pill with a thiazide
diuretic instead of a beta-blocker could reduce the same
outcomes by 44% and 37%, respectively, if used by all
U.S. adults 55 years old for primary prevention (77).
Nonpharmacologic and global interventions. Beyond
pharmacologic approaches, inexpensive interventions
may also bring large health rewards. Adherence to the
Mediterranean diet reduces the risk for the metabolic
syndrome and its individual components according to a
meta-analysis of 50 studies (78). Even low-volume phys-
Figure 4 Depiction of Intraplaque Hemorrhage by MRI
Examples of magnetic resonance imaging (MRI) in 2 patients with carotid intraplaq
thrombus imaging demonstrates high signal in a large right common carotid artery
in the left common carotid artery in the second patient (D, arrowheads). Noncontr
onstrate no significant stenosis in either patient. Reproduced with permission fromical exercise (defined as 15 min per day or 90 min perweek) was independently associated with a 20% reduction
in cardiovascular mortality risk (79). Yet higher impact
may be expected by implementing policies that affect the
population at large, from reductions in sodium in the
food supply to development of walking/biking trails that
promote healthier environments (80).
Statin therapy and dyslipidemia. Simulation studies sug-
gested that inexpensive generic statins would be cost effec-
tive if primary prevention indications were expanded to
persons with lower LDL cholesterol levels than currently
recommended, or to moderate-risk or high-risk persons
regardless of LDL cholesterol concentration (81,82). Mea-
suring CRP and treating with rosuvastatin if 2 mg/dl
(JUPITER-like strategy) was also deemed cost effective
(83). Nonetheless, statin therapy for patients with low LDL
cholesterol but high CRP was put into question by a
post-hoc analysis of the Heart Protection Study, the largest
randomized trial to date of statin therapy versus placebo in
patients with high vascular risk (many of them with known
prior CVD) and that encompassed 4,500 events. The
study found no evidence of relatively increased protection of
simvastatin 40 mg daily for 5 years for patients with higher
CRP levels. In fact, simvastatin provided comparable protec-
tive effects for patients with CRP levels 1 mg/dl (84). The
SATURN (Study of Coronary Atheroma by Intravascular
eding (upper row) and without carotid intraplaque bleeding (bottom row). Direct
e in the first patient (A, arrowheads), which is absent in a similarly large plaque
giograms (B and E, arrows) and contrast-enhanced angiograms (C and F) dem-
chi et al. (58).ue ble
plaqu
ast an
NoguUltrasound: Effect of Rosuvastatin Versus Atorvastatin) trial
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daily for 2 years using IVUS-derived coronary atheroma as a
primary endpoint. Despite lower LDL and higher HDL levels
achieved with rosuvastatin, both regimens resulted in compara-
le atheroma volume reductions of approximately 1% (85).
The optimal approach to pharmacologically modulate the
potentially atheroprotective effects of HDL cholesterol con-
tinued to be controversial. The AIM-HIGH (Athero-
thrombosis Intervention in Metabolic Syndrome With Low
HDL/High Triglycerides: Impact on Global Health Out-
comes) study evaluated the effects of extended-release niacin
versus placebo added on top of intensive statin therapy in
3,414 stable patients with established CVD, low LDL levels
(median 74 mg/dl), median HDL concentrations of 35
mg/dl, and median triglyceride levels of 163 mg/dl (86).
Despite a 25% increase in HDL cholesterol and 31% and
14% reductions in triglycerides and LDL cholesterol levels,
respectively, the trial was stopped prematurely after 3 years
because of lack of efficacy of niacin to improve cardiovas-
cular outcomes (Fig. 6). Whether these findings can be
extrapolated to patients with acute syndromes or higher
baseline levels of LDL cholesterol remains to be deter-
mined. Novel cholesteryl ester transfer protein inhibitors
may raise HDL cholesterol without concomitant undesired
increases in blood pressure. In the dal-PLAQUE (Safety
and Efficacy of Dalcetrapib on Atherosclerotic Disease
Using Novel Non-Invasive Multimodality Imaging) study,
dalcetrapib did not show proatherogenic effects as demon-
strated by MRI and positron emission tomography/CT
Figure 5 Number of Preventive Drugs According to Regional So
Medications taken for secondary prevention per person in the PURE (Prospective U
2 drugs (orange bars), or 3 drugs (light gray bars). Reproduced with permissionwhen administered over 24 months to stable patients withhigh cardiovascular risk. Conversely, there was no evidence
of reductions in arterial inflammation by raising HDL
cholesterol with dalcetrapib (87). Merely increasing HDL
cholesterol may not lead to improved outcomes based on a
large series of subjects ranging from healthy volunteers to
patients with CHD, where reduced HDL cholesterol efflux
onomic Status
Rural Epidemiological) study: no drug (dark gray bars), 1 drug (blue bars),
Yusuf et al. (73).
Figure 6 Main Results of the AIM-HIGH Trial
In the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With
Low HDL/High Triglycerides) trial, addition of niacin to statin therapy (red line)
when compared to placebo (black line) did not result in a reduction of the pri-
mary outcome (coronary heart disease death, nonfatal myocardial infarction,
ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-
driven coronary or cerebral revascularization). No.  number. Reproduced with
permission from the AIM-HIGH Investigators (86).cioec
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cholesterol) was independently associated with increased
CIMT and CHD after adjusting for conventional risk
factors, including HDL cholesterol or apolipoprotein A-1
concentrations (Fig. 7). Importantly, HDL plasma levels only
explained 40% of the cholesterol efflux capacity (88). Similarly,
HDLwas noted to have reduced anti-inflammatory capacity in
the setting of acute coronary syndromes (89).
Diabetes mellitus and hypertension. After previous data
demonstrating improved outcomes for patients with newly
diagnosed or longstanding diabetes with intensive risk factor
control, a study involving 3,000 subjects evaluated the
hypothesis that screening for early detection of diabetes
followed by intensive multifactorial therapy would lead to
improved prognosis. After a mean follow-up of 5.3 years,
the intensive approach resulted in improvements in risk
factor control but nonsignificant reductions in mortality and
incident cardiovascular events (90). Following on the po-
tential harms associated with tight blood pressure control in
established diabetes, previously shown in the ACCORD
(Action to Control Cardiovascular Risk in Diabetes) study,
a meta-analysis of randomized trials including 37,000
patients reported that lowering systolic blood pressure to
135 mm Hg (in comparison with 140 mm Hg) was
associated with a 10% reduction in mortality, 17% reduction
in stroke, 20% increase in serious adverse effects, and no
differences in other microvascular and macrovascular out-
comes. Lowering levels to 130 mm Hg continued to
reduce risk of stroke only, at the expense of a 40% rate of
serious adverse events (91). Similar findings may also apply
to another high-risk subgroup of patients, those with
established atherothrombosis, in whom reductions of blood
pressure to 130/80 mm Hg provided cerebrovascular and
renal but not cardiac protection in a post-hoc analysis of a
large trial (92). The ACCORD study also randomly as-
signed patients with type 2 diabetes to intensive or standard
glucose-lowering therapy, and was stopped prematurely after
3.5 years because of increased mortality in the intensive arm.
In 2011, extended follow-up to 5 years confirmed an
increase in all-cause mortality (HR: 1.19; 95% CI: 1.03 to
Figure 7 Odds of CHD According to HDL Cholesterol
Efflux Capacity and Standard Risk Factors
Odds ratios are adjusted by age and sex, and for continuous variables indicate
odds per 1 SD increase. High-density lipoprotein (HDL) cholesterol efflux capac-
ity is significantly protective of coronary heart disease (CHD). CI  confidence
interval; LDL  low-density lipoprotein. Reproduced with permission from Khera
et al. (88).1138, p  0.02) but a reduction in nonfatal myocardial
nfarction (HR: 0.82; 95% CI: 0.70 to 0.96; p 0.01) in the
intensive arm (93). Regarding the optimal oral glucose-
lowering therapy for diabetes, a Danish nationwide study
including 107,000 participants followed up for a median
of 3.3 years pointed to increased cardiovascular risk with
most sulphonylureas in comparison with metformin when
used as single therapy (94).
Antithrombotic therapy. Further evidence became avail-
able on the safety of combining clopidogrel and proton
pump inhibitors for myocardial infarction survivors, regard-
less of CYP2C19 genotype (95). Persistently high platelet
reactivity under clopidogrel therapy is associated with re-
current events after percutaneous revascularization. The
GRAVITAS (Gauging Responsiveness With A VerifyNow
Assay—Impact on Thrombosis and Safety) study randomly
allocated 2,214 patients with high residual platelet reactivity
to a clopidogrel 600-mg loading dose plus 150 mg daily
thereafter or to a standard dose (75 mg daily). High-dose
clopidogrel failed to reduce the 6-month incidence of
cardiovascular death, nonfatal myocardial infarction, or
stent thrombosis (96). In a separate cohort and despite
intensification of antiplatelet therapy based on reactivity
tests, event rates remained almost double in patients with
residual high platelet reactivity (97). Higher doses of clopi-
dogrel (225 mg daily) were able to reduce platelet reactivity
to normal levels in carriers of CYP2C19 loss-of-function
variants, but whether that translates into clinical benefit
remains unknown (98). The multinational PLATO (Plate-
let Inhibition and Patient Outcomes) trial previously
showed that ticagrelor outperformed clopidogrel in prevent-
ing recurrent events and death after among patients with
coronary syndromes. The reasons for lower beneficial effects
in North America remain incompletely understood, although a
higher maintenance dose of aspirin in the United States may be
partly responsible. Aspirin inhibits prostacyclin in a dose-
dependent manner, and since prostacyclin probably potentiates
P2Y12 antagonists synergically, this inhibition may lead to
reduced antiplatelet activity at higher aspirin doses, particularly
for ticagrelor, the most potent P2Y12 blocker (99).
Although beyond the scope of this review, novel factor Xa
nhibitors that do not require routine blood monitoring
ompared favorably to warfarin for patients with atrial
brillation. However, when these and other novel anti-
hrombotic agents have been added to standard antiplatelet
herapy after an acute coronary syndrome, there have been
ncreased bleeding rates without clear atherothrombotic
rotection (100–102). The exception came from the AT-
AS ACS 2–TIMI 51 (Anti-Xa Therapy to Lower Car-
iovascular Events in Addition to Standard Therapy in
ubjects With Acute Coronary Syndrome–Thrombolysis In
yocardial Infarction 51) study, where 15,000 patients
ith an acute coronary syndrome were randomly allocated
:1:1 to rivaroxaban 5 mg per 12 h, rivaroxaban 2.5 mg per
2 h, or placebo (103). After a mean follow-up of 13
939JACC Vol. 60, No. 10, 2012 Sanz et al.
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comparison with placebo (p  0.008). Additionally, the
lower dose also resulted in 34% and 32% reductions in
cardiovascular and all-cause mortality, respectively (p 
0.002 for both) (Fig. 8). Major and minor bleeding
increased with rivaroxaban, although fatal bleeding rates
were not significantly different.
Figure 8 Cumulative Incidence of Events by Rivaroxaban Dose
In the ATLAS ACS 2–TIMI 51 trial, (A, B) the primary efficacy endpoint (cardiovasc
(C, D) only the smaller dose is associated with survival benefit. CI  confidence i
Highlights of the Year 2011 in AtherothrombosisTable 2 Highlights of the Year 2011 in Atherothrombosis
An emphasis was placed on promotion of health as measured by 7 parameters as o
Increasing evidence supported the links between vascular disease, aging, and degen
Large, thin-cap fibroatheromas with small luminal area were prospectively associate
Coronary calcification remained the most powerful noninvasive predictor of cardiova
Risk factor control remains markedly poor worldwide (PURE study and others) (69–7
Policies to promote cardiovascular health and medication affordability/adherence c
Extended-release niacin added to statins in established CVD increased HDL choleste
Reduced HDL functional activity was associated with subclinical CVD beyond HDL se
Further data supported moderate (vs. intensive) blood pressure and glucose control
Increasing doses of clopidogrel for high residual platelet reactivity so far failed to sh
The factor Xa inhibitor rivaroxaban reduced combined death, myocardial infarction,CVD  cardiovascular disease; HDL  high-density lipoprotein.Conclusions
The year 2011 brought both promising developments and
sobering realizations regarding epidemiology, diagnosis, and
management of cardiovascular risk factors and atherothrom-
botic CVD. The most important findings are summarized
in Table 2.
e ATLAS ACS 2–TIMI 51 Trial
ath, myocardial infarction, or stroke) is reduced by both rivaroxaban doses, but
. Reproduced with permission from Mega et al. (103).
d to just prevention of disease (1,74).
e brain disease (24–26).
nonculprit coronary events (PROSPECT study) (51).
outcomes (40,41,53,54).
e large impact on CVD control (75–77,80).
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